$MELI closed at $1,104.20, about 45% decline from its ATH of $2,020. Since 2012, there has been 5 instances when $MELI dropped more than 40% and recovered. Given the company’s recent performance and the management’s historical track record, I believe 6th time is not an exception.
@DrJesseMorse Great resource, thank you! Is there a peptide that you recommend your patients who are in their 30s-40s who don’t have any health issues, adhere to healthy lifestyle with disciplined diet and constant exercise? Just to help with overall metabolic health, recovery & muscle growth.
$MELI Q3 26 ER “Net rev & income of $10,750 million, up 45% YoY and 41% FX-neutral / Income from operations of $676 million, with a 6.3% margin / Net income of $448 million, with a 4.2% margin / TPV of $109 billion, up 53% YoY and 51% FX-neutral / GMV of $23 billion, up 38% YoY”.
@Ihartitz Yea, McMillan’s return is a threat for volume target, for sure. I have Godwin now, such lackluster performance in two weeks. Baker better get his 💩 together rather quickly if they want to keep playoff hopes alive. Still somewhat optimistic for Godwin as a flex?